Royal Bank Of Canada Impel Pharmaceuticals Inc Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$1.08 - $2.75 $117 - $299	109 New	109 $0
Q3 2022 Nov 14, 2022	BUY	$5.78 - $9.32 $433 - $699	75 New	75 $0
Q2 2022 Aug 15, 2022	SELL	$5.83 - $10.12 $2,483 - $4,311	-426 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.86 - $9.85 $5,889 - $9,899	-1,005 Reduced 70.23%	426 $3,000
Q4 2021 Feb 14, 2022	BUY	$8.33 - $12.14 $6,039 - $8,801	725 Added 102.69%	1,431 $13,000
Q3 2021 Nov 15, 2021	BUY	$8.38 - $26.13 $2,815 - $8,779	336 Added 90.81%	706 $8,000
Q2 2021 Aug 16, 2021	BUY	$7.33 - $15.2 $2,712 - $5,624	370 New	370 $3,000

14.4K

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.